HOWSON TAMAR D 4

What Happened

• Tamar D. Howson, a director of IMMUNIC, Inc. (IMUX), was granted a derivative award (options) covering 25,370 shares on June 29, 2026. The Form 4 reports an acquisition at $0.00 because this filing records the grant of options rather than an exercised purchase; no cash value or exercise price is shown on the Form 4.
• Footnotes indicate these options were conditionally approved by the Board on March 27, 2026 and required an amendment to the company’s 2019 Omnibus Equity Incentive Plan; that amendment was approved by stockholders at the company’s 2026 Annual Meeting on June 29, 2026. The options are fully vested as of March 27, 2026.

Key Details

• Transaction date: 2026-06-29; transaction type: Award/Grant of derivative securities (code A).
• Reported price: $0.00 on the Form 4 (reflects a grant, not an exercised purchase).
• Shares/options granted: 25,370.
• Shares owned after the transaction: not disclosed in this filing.
• Notable footnotes: F1 — grant conditionally approved by Board (3/27/2026) and approved by stockholders (6/29/2026). F2 — options fully vested as of 3/27/2026.
• Filing timeliness: report covers the transaction date 2026-06-29 and was filed with accession 0001193805-26-000889 (no late filing indicated).

Context

• This filing documents an option award (a derivative grant). It is not an exercise or a sale — no shares were sold or purchased for cash in this Form 4. Options give the holder the right to buy shares in the future under plan terms; the Form 4 here does not disclose the option exercise price or the future cash required to convert options into common shares.
• Award grants to directors are common and are part of compensation; they are factual disclosures and do not by themselves indicate the director’s personal trading view.